In a Lower Manhattan office with nine employees, Kathleen McMahon is building software she hopes will solve what she calls biosecurity's central asymmetry: the speed mismatch between emerging biological threats and our ability to stop them.
Valthos, the startup she co-founded after running Palantir's Life Sciences division, raised $30 million in seed funding this fall—a sizable early bet from OpenAI Startup Fund, Lux Capital, and Founders Fund. The October announcement positioned the company as something of a moonshot: an attempt to collapse the agonizing timeline between detecting a novel pathogen and fielding a medical response.
Whether the software can deliver on that promise remains an open question. But the backing alone says something about where venture capital sees opportunity—and risk. At a moment when engineered biological threats have migrated from the realm of speculative fiction to congressional testimony, Valthos is pitching a real-time defense system built on aggregated biological data, OpenAI's reasoning models, and sequence-analysis pipelines that governments and pharmaceutical companies might actually use.
The company isn't disclosing customers yet. No federal contracts have been announced publicly, though Valthos does appear in the Medical Technology Enterprise Consortium member directory, a Department of Defense-linked network that tends to signal government ambitions. The pitch, for now, is about speed: software that can identify emerging biological sequences, assess threat levels, and prioritize countermeasure design faster than manual workflows allow.
That automation piece is where the AI comes in. Valthos uses OpenAI's models as what the company describes as a "reasoning layer," tying together biological models and decision trees in ways that would otherwise require extensive human coordination. The system pulls from air and wastewater monitoring data, analyzes patterns, and flags anomalies—essentially building a kind of early-warning apparatus for public health agencies and life sciences stakeholders.
OpenAI Startup Fund's involvement here tracks with a broader pattern. Just weeks after the Valthos round closed, the fund led a $15 million investment in Red Queen Bio, another AI-focused biosecurity venture. Jason Kwon, OpenAI's Chief Strategy Officer, said in a prepared statement that Valthos is "pushing the frontier of protection and defense"—the sort of language that signals strategic interest beyond a single check.
Lux Capital, long a backer of companies at the intersection of hard science and software, deployed partners Josh Wolfe and Brandon Reeves to the deal. Tess van Stekelenburg, another Lux partner, is also listed as Valthos co-founder, an unusual dual role that suggests deep conviction in the thesis. Van Stekelenburg, who has a computational neuroscience background from Oxford, described the work as building "new software infrastructure for biodefense" and laying groundwork for what she termed "adaptive precision therapeutics."
Founders Fund rounded out the lead group—Peter Thiel's firm has long favored companies tackling civilizational-scale problems, and biosecurity fits neatly into that mandate.
McMahon's framing centers on asymmetry. "The core issue in biodefense is asymmetry," she said in the company's press release. "We're building tools so front-line experts can move as fast as the threats." It's a tidy articulation of the problem, though one that elides the considerable technical and regulatory hurdles between concept and deployed system.
Thirty million dollars is a substantial seed round for a company that launched with fewer than a dozen people. One industry outlet characterized it as among the largest early-stage investments in AI biodefense—a claim that's hard to verify given the opacity of defense-adjacent funding, but not implausible given the pedigree of the backers and the category's nascent state.
The capital will go toward scaling the platform and hiring engineers. As of early March, the company's careers page showed active recruiting, and LinkedIn profiles suggest the headcount has climbed to at least eleven. That's measured growth, perhaps appropriately so for a company working in a domain where moving too fast invites scrutiny—or worse, unintended consequences.
There's also the question of market readiness. Government procurement cycles are notoriously slow, and selling biosecurity software requires navigating clearance levels, compliance regimes, and entrenched bureaucracies that don't always move at startup velocity. Valthos will need to prove not just that its software works, but that it can integrate into existing workflows without creating new vulnerabilities.
Still, the round reflects a growing investor appetite for startups applying frontier AI to biological threats—particularly those with defensible technical moats and government-facing potential. The threat landscape has shifted enough that what once seemed like science fiction now commands serious capital and serious talent.
Whether Valthos can turn that conviction into a working biodefense system is the harder question. The company is early, the challenge is enormous, and the stakes are about as high as they get. But for now, at least, the bet has been made.
